Open an account

Candel Therapeutics

CADL · NASDAQ

$8.64+$0.43 (+5.24%)TodayMarket closed ·
Prev close $8.21

About CADL

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2021-07-27. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

Employees
55
Headquarters
Needham, Massachusetts
Listed
Jul 27, 2021
Sector
Health Care
Industry
Biotechnology
Website
candeltx.com

CADL key statistics

Market cap
661.12M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.00M
Volume
1.13M
Open price
$8.17
High today
$8.84
Low today
$8.13
52 Week high
$14.00
52 Week low
$4.35

Candel Therapeutics (CADL) at a glance

As of Oct 20, 2026, Candel Therapeutics (CADL) shares are priced at $8.64, giving the company a market cap of 661.12M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.13 and $8.84. The current price is 6.3% above the day's low and 2.3% below its high.

Volume so far is 1.13M shares, in line with the average of 1.00M shares a day.

Over the past year Candel Therapeutics has ranged from $4.35 to $14.00, and now sits 44% of the way up that range.

Candel Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.52 per share against an estimate of -$0.2414.

The average analyst price target is $22.18, 156.8% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 9 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $22.18
Low
$15.15
Now
$8.64
High
$30.45

CADL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 82.4% on average.

  1. Q4 FY23: reported -$0.38 per share against an estimate of -$0.1632
  2. Q4 FY24: reported -$0.40 per share against an estimate of -$0.2321
  3. Q1 FY25: reported $0.13 per share against an estimate of -$0.306
  4. Q2 FY25: reported -$0.09 per share against an estimate of -$0.1734
  5. Q3 FY25: reported -$0.21 per share against an estimate of -$0.1888
  6. Q4 FY25: reported -$0.54 per share against an estimate of -$0.2508
  7. Q1 FY26: reported -$0.14 per share against an estimate of -$0.3232
  8. Q2 FY26: reported -$0.52 per share against an estimate of -$0.2414

CADL news

  • Press releaseGlobe Newswire

    Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

  • Nabaparna Bhattacharya

    Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

  • Press releaseGlobe Newswire

    Candel Therapeutics to Present at Upcoming Investor Conferences

  • Press releaseGlobe Newswire

    Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

  • Evette Mitkov

    Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseGlobe Newswire

    Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

  • 12 Health Care Stocks Moving In Friday's Intraday Session

Similar companies

Companies in the same industry as Candel Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.